Kymera Therapeutics Reports Q2 2026 Financial Results

What Happened
Kymera Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2026 and furnished a related press release as Exhibit 99.1 to a Form 8-K filed on August 5, 2026. The Form 8-K states the press release is being furnished (not “filed”) and therefore is not subject to Section 18 liability or automatically incorporated by reference in other SEC filings. The report is signed by Nello Mainolfi, Ph.D., President and Chief Executive Officer.

Key Details

• Filing date: August 5, 2026 (Form 8-K).
• Reporting period: quarter ended June 30, 2026 (Q2 2026).
• Exhibit: Press release issued by Kymera Therapeutics furnished as Exhibit 99.1.
• Legal note: Information is furnished, not “filed” under Section 18 of the Exchange Act and is not incorporated by reference except where expressly stated.

Why It Matters
This 8-K signals Kymera has released its quarterly earnings/financial results; investors should review the furnished press release (Exhibit 99.1) for revenue, net loss, cash position, and operational highlights that could affect the stock. The filing’s “furnished, not filed” status is a legal disclosure detail — it does not change the substance of the results but limits certain liabilities and incorporation-by-reference implications in future SEC filings.